Table 2. Clinicopathological characteristics of 322 HBV-related HCC patients after PSM.
| Variable | TP53 249Ser mutation | |||
|---|---|---|---|---|
| Non-mutation group (n=161) | Mutation group (n=161) | OR* (95% CI) | P value* | |
| Age (years) | ||||
| ≤46 | 81 | 81 | 1 | |
| >46 | 80 | 80 | 1.00 (0.65–1.55) | 1.000 |
| Gender | ||||
| Male | 140 | 144 | 1 | |
| Female | 21 | 17 | 0.79 (0.40–1.55) | 0.490 |
| Race | ||||
| Han | 102 | 93 | 1 | |
| Minority | 59 | 68 | 1.26 (0.81–1.98) | 0.305 |
| BMI | ||||
| ≤25 | 132 | 133 | 1 | |
| >25 | 29 | 28 | 0.96 (0.54–1.70) | 0.884 |
| Smoking status | ||||
| None | 106 | 104 | 1 | |
| Ever | 55 | 57 | 1.06 (0.67–1.67) | 0.815 |
| Drinking status | ||||
| None | 102 | 93 | 1 | |
| Ever | 59 | 68 | 1.26 (0.81–1.98) | 0.305 |
| Child-Pugh class | ||||
| A | 135 | 126 | 1 | |
| B | 26 | 35 | 1.43 (0.74–2.76) | 0.288 |
| BCLC stage | ||||
| A | 105 | 95 | 1 | |
| B | 21 | 29 | 1.53 (0.82–2.85) | |
| C | 35 | 37 | 1.17 (0.68–2.00) | 0.402 |
| TP53 expressiona | ||||
| Negative | 69 | 25 | 1 | |
| Positive | 67 | 112 | 4.61 (2.67–8.00) | <0.001 |
| TACE status | ||||
| Before hepatectomy | ||||
| No | 122 | 135 | 1 | |
| Yes | 39 | 26 | 0.60 (0.35–1.05) | 0.073 |
| After hepatectomy | ||||
| No | 71 | 73 | 1 | |
| Yes | 90 | 88 | 0.95 (0.61–1.48) | 0.823 |
| Cirrhosis | ||||
| No | 15 | 22 | 1 | |
| Yes | 146 | 139 | 0.65 (0.324–1.30) | 0.224 |
| Serum AFPb | ||||
| ≤400 (ng/mL) | 85 | 80 | 1 | |
| >400 (ng/mL) | 66 | 66 | 1.06 (0.67–1.68) | 0.795 |
| Radical resection | ||||
| Yes | 102 | 102 | 1 | |
| No | 59 | 59 | 1.00 (0.64–1.57) | 1.000 |
| Pathological gradec | ||||
| Good | 14 | 5 | 1 | |
| Moderate | 127 | 124 | 2.73 (0.96–7.82) | |
| Poor | 7 | 4 | 1.60 (0.34–7.90) | 0.130 |
| Antiviral therapy | ||||
| No | 111 | 103 | 1 | |
| Yes | 50 | 58 | 1.30 (0.82–2.06) | 0.273 |
| Oncological behavior | ||||
| Tumor size | ||||
| ≤5 cm | 56 | 50 | 1 | |
| >5 cm | 105 | 111 | 1.18 (0.74–1.88) | 0.477 |
| No. of tumors | ||||
| Single (n=1) | 122 | 118 | 1 | |
| Multiple (n>1) | 39 | 43 | 1.14 (0.69–1.88) | 0.609 |
| Capsule | ||||
| Complete | 63 | 61 | 1 | |
| Incomplete | 72 | 75 | 0.99 (0.52–1.91) | |
| Absence | 26 | 25 | 1.08 (0.67–1.74) | 0.945 |
| Regional invasion | ||||
| Absence | 139 | 136 | 1 | |
| Presence | 22 | 25 | 1.16 (0.63–2.16) | 0.636 |
| Intrahepatic metastasis | ||||
| Absence | 70 | 73 | 1 | |
| Presence | 91 | 88 | 0.93 (0.60–1.44) | 0.737 |
| Vascular invasion | ||||
| Absence | 135 | 135 | 1 | |
| Presence | 26 | 26 | 1.00 (0.55–1.81) | 1.000 |
| PVTT | ||||
| No | 140 | 136 | 1 | |
| vp1 | 0 | 6 | NA | |
| vp2 | 8 | 3 | 0.39 (0.10–1.49) | |
| vp3 | 11 | 13 | 1.22 (0.53–2.81) | |
| vp4 | 2 | 3 | 1.54 (0.25–9.39) | 0.657 |
a, TP53 expression information was unavailable for 49 patients. b, AFP information was unavailable for 25 patients. c, pathological grade information was unavailable for 41 patients. *, OR and P value for univariate analysis of logistic regression model. AFP, alpha-fetoprotein; TACE, transarterial chemoembolization; BMI, body mass index; PVTT, portal vein tumor thrombus; OR, odds ratio; 95% CI, 95% confidence interval.